Clinical efficacy of ribavirin in the treatment of genital herpes simplex virus infection.
48 patients participated in a double-blind placebo-controlled study conducted to evaluate the efficacy of ribavirin in the treatment of herpes simplex virus genital infection. Study design did not allow a conclusion regarding usefulness of the drug in preventing recurrences. Ribavirin treatment (800 mg/day p.o) for 10 days reduced disease severity and promoted recovery as compared with placebo treatment.
D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006561:Herpes Simplex / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010919:Placebos; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use*; D012263:Ribonucleosides / Q000627:therapeutic use*
D010919:Placebos; D012263:Ribonucleosides; D012254:Ribavirin